Targeting STING with covalent small-molecule inhibitors

Simone M. Haag, Muhammet F. Gulen, Luc Reymond, Antoine Gibelin, Laurence Abrami, Alexiane Decout, Michael Heymann, F. Gisou van der Goot, Gerardo Turcatti, Rayk Behrendt and Andrea Ablasser ()
Additional contact information
Simone M. Haag: Swiss Federal Institute of Technology Lausanne (EPFL)
Muhammet F. Gulen: Swiss Federal Institute of Technology Lausanne (EPFL)
Luc Reymond: Swiss Federal Institute of Technology Lausanne (EPFL)
Antoine Gibelin: Swiss Federal Institute of Technology Lausanne (EPFL)
Laurence Abrami: Swiss Federal Institute of Technology Lausanne (EPFL)
Alexiane Decout: Swiss Federal Institute of Technology Lausanne (EPFL)
Michael Heymann: Swiss Federal Institute of Technology Lausanne (EPFL)
F. Gisou van der Goot: Swiss Federal Institute of Technology Lausanne (EPFL)
Gerardo Turcatti: Swiss Federal Institute of Technology Lausanne (EPFL)
Rayk Behrendt: Institute for Immunology, Faculty of Medicine, Technical University Dresden
Andrea Ablasser: Swiss Federal Institute of Technology Lausanne (EPFL)

Nature, 2018, vol. 559, issue 7713, 269-273

Abstract: Abstract Aberrant activation of innate immune pathways is associated with a variety of diseases. Progress in understanding the molecular mechanisms of innate immune pathways has led to the promise of targeted therapeutic approaches, but the development of drugs that act specifically on molecules of interest remains challenging. Here we report the discovery and characterization of highly potent and selective small-molecule antagonists of the stimulator of interferon genes (STING) protein, which is a central signalling component of the intracellular DNA sensing pathway1,2. Mechanistically, the identified compounds covalently target the predicted transmembrane cysteine residue 91 and thereby block the activation-induced palmitoylation of STING. Using these inhibitors, we show that the palmitoylation of STING is essential for its assembly into multimeric complexes at the Golgi apparatus and, in turn, for the recruitment of downstream signalling factors. The identified compounds and their derivatives reduce STING-mediated inflammatory cytokine production in both human and mouse cells. Furthermore, we show that these small-molecule antagonists attenuate pathological features of autoinflammatory disease in mice. In summary, our work uncovers a mechanism by which STING can be inhibited pharmacologically and demonstrates the potential of therapies that target STING for the treatment of autoinflammatory disease.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (18)

Downloads: (external link)
https://www.nature.com/articles/s41586-018-0287-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:559:y:2018:i:7713:d:10.1038_s41586-018-0287-8

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-018-0287-8

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().